Physician profile
Mitchell Jay Mandel
NPI 1710076427
$15,691.31
in general payments reported to CMS, 2019-2025
43 companies · $4,014 in 2025
The $4,014 reported for 2025 was more than what 88% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,896 · 2020: $357 · 2021: $793 · 2022: $1,544 · 2023: $1,741 · 2024: $5,345 · 2025: $4,014.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,374 · Travel and Lodging: $1,532 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,374.08 |
| Travel and Lodging | $1,531.87 |
| Education | $194.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $3,536.79 | 2019-2025 | Xeomin |
| Janssen Biotech, INC. | $1,587.12 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Pfizer INC. | $1,453.22 | 2019-2025 | |
| Revance Therapeutics, INC. | $1,238.16 | 2024-2025 | Daxxify |
| Abbvie INC. | $1,176.64 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $1,103.04 | 2024-2025 | Zoryve |
| Lilly USA, LLC | $789.12 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $520.05 | 2021-2025 | Opzelura, Opzelura |
| Galderma Laboratories, L.P. | $443.90 | 2019-2025 | Nemluvio |
| Novartis Pharmaceuticals Corporation | $435.90 | 2019-2025 | |
| Dermavant Sciences, INC. | $406.75 | 2022-2024 | Vtama |
| Amgen INC. | $378.39 | 2019-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $354.35 | 2022-2025 | Winlevi, Absorica Ld, Ilumya |
| Almirall LLC | $343.46 | 2019-2025 | Klisyri, Seysara |
| Genzyme Corporation | $229.31 | 2021-2025 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Mandel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.